QALYBHRe: Impact of a Carrier (Infection, Colonization) of Highly Bacteria Resistance on the Patient's Quality of Life Hospital Environment

Sponsor

Hospices Civils de Lyon (Other)

Overall Status

Withdrawn

CT.gov ID

NCT04226001

Collaborator

(none)

Enrollment

2.5

Anticipated Duration (Months)

Study Details

Study Description

Brief Summary

The quality of life of carriers detected infected or colonized by emerging highly resistant bacteria (BHRe) following the implementation of specific hygiene measures during the discovery of the microorganism has been little studied. To date, there have been no studies to determine the quality of life (QoL) in France of patients with hospitalized HBHRD.

Condition or Disease	Intervention/Treatment	Phase
Bacterial Infections	Other: Quality of life questionnaire

Study Design

Study Type:

Observational

Actual Enrollment :

0 participants

Observational Model:

Cohort

Time Perspective:

Prospective

Official Title:

Impact of a Carrier (Infection, Colonization) of Highly Bacteria Resistance on the Patient's

Actual Study Start Date :

Nov 16, 2020

Anticipated Primary Completion Date :

Feb 1, 2021

Anticipated Study Completion Date :

Feb 1, 2021

Arms and Interventions

Arm	Intervention/Treatment
Patients Patients screened for carriers infected or colonized by emerging highly resistant bacteria.	Other: Quality of life questionnaire Quality of life questionnaire

Arm

Intervention/Treatment

Patients

Patients screened for carriers infected or colonized by emerging highly resistant bacteria.

Other: Quality of life questionnaire

Quality of life questionnaire

Outcome Measures

Primary Outcome Measures

Impact of the implementation of Complementary Hygiene Precautions following a carrier of emerging highly resistant bacteria on the quality of life of hospitalized patients [12 months]
Measurement of the decrease in utility corresponding to the deterioration of the QOL of patients since the implementation of the Additional Hygiene Precautions (PCH) following the discovery of their emerging highly resistant bacteria (BHRe).

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Age> 18 years old
Have a positive BHRe screening during the hospital stay and / or have a positive BHRe clinical sample during the hospital stay
Conscious patients
All types of stays in the hospital sector
All pathologies

Exclusion Criteria:

Known patients with BHRe before hospitalization
PCH immediately upon admission (history of hospitalization abroad, patients contacted during a previous hospitalization)
Cognitive problem
Patients not proficient in French (requiring an interpreter)
Patients under guardianship

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

Hospices Civils de Lyon

Investigators

Principal Investigator: David NARBEY, MD, Hospices Civils de Lyon

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

Responsible Party:

Hospices Civils de Lyon

ClinicalTrials.gov Identifier:

NCT04226001

Other Study ID Numbers:

69HCL19_0022
2019-A00074-53

First Posted:

Jan 13, 2020

Last Update Posted:

Nov 17, 2020

Last Verified:

Nov 1, 2020

Studies a U.S. FDA-regulated Drug Product:

Studies a U.S. FDA-regulated Device Product:

Additional relevant MeSH terms:

Infections

Communicable Diseases

Bacterial Infections

Study Results

No Results Posted as of Nov 17, 2020